Raju Mohan - Jun 5, 2023 Form 4 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Chief Executive Officer, Director
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Stock symbol
VTYX
Transactions as of
Jun 5, 2023
Transactions value $
-$1,030,652
Form type
4
Date filed
6/6/2023, 07:18 PM
Previous filing
May 5, 2023
Next filing
Jul 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VTYX Common Stock Sale -$925K -27K -1.75% $34.32 1.52M Jun 5, 2023 Direct F1, F2
transaction VTYX Common Stock Sale -$105K -3.03K -0.2% $34.67 1.51M Jun 5, 2023 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 28, 2022.
F2 Represents the weighted average share price of an aggregate total of 26,966 shares sold in the price range of $33.63 to $34.6296. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
F3 Represents the weighted average share price of an aggregate total of 3,034 shares sold in the price range of $34.63 to $34.7634. The reporting owner undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.